Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

NBIX US Equity

Neurocrine Biosciences IncHealth Care · Biological Products, (No Diagnostic Substances) · CIK 914475 · FY ends Dec 31
$155.54
+1.31 (+0.85%)
USD · as of 2026-08-19 · marketstack
9 8-K filings · 0 13D · 4 13G
DateEventWhat happened / filerSource
2026-07-318-K 9.01Financial statements and exhibits (amendment)sec.gov ↗
2026-07-308-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-07-2713G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by JPMORGAN CHASE & COsec.gov ↗
2026-05-288-K 5.07Submission of matters to a vote of security holderssec.gov ↗
2026-05-288-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
2026-05-188-K 7.01Regulation FD disclosuresec.gov ↗
2026-05-188-K 2.03Creation of a direct financial obligationsec.gov ↗
2026-05-188-K 2.01Completion of acquisition or disposition of assetssec.gov ↗
2026-05-188-K 1.01Entry into a material definitive agreementsec.gov ↗
2026-05-058-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-04-3013GSchedule 13G filed — ≥5% beneficial owner (passive) · by VANGUARD CAPITAL MANAGEMENT LLCsec.gov ↗
2026-04-068-K 1.01Entry into a material definitive agreementsec.gov ↗
2026-03-2713G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by VANGUARD GROUP INCsec.gov ↗
2026-02-118-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-01-2113GSchedule 13G filed — ≥5% beneficial owner (passive) · by JPMORGAN CHASE & COsec.gov ↗
2025-11-248-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
2025-10-288-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2025-10-28

Every row is a filed document, checked against its EDGAR index.